Navigation Links
Acclarent, Inc. Awarded 'Red Herring 100 North America'
Date:5/28/2009

MENLO PARK, Calif., May 29 /PRNewswire/ -- Acclarent, Inc., a leading medical technology company dedicated to designing, developing and commercializing devices that address conditions affecting the ear, nose and throat today announced that it won the "Red Herring 100 North America" award. The Red Herring editorial team deploys a detailed process to whittle down a pool of 1,200 eligible, promising companies to decide on the top 100 winners of this important North American award. Evaluations are made on both quantitative and qualitative criteria, such as financial performance, innovation, management, global strategy, and ecosystem integration. Alex Vieux, CEO of Red Herring, presented the award to the winning companies in San Diego on May 14, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090529/LA24185LOGO)

"Acclarent will cure and help millions of Americans over the years. This represents innovation excellence at its best led by pristine investors and a seasoned team. It fully deserves its place within the Red Herring 100 North America," said Mr. Vieux.

"Being recognized by Red Herring as one of the most promising private companies in North America is a tremendous accomplishment. On behalf of the 300 deserving employees at Acclarent, I would like to thank Red Herring for this prestigious award," said Bill Facteau, President and CEO of Acclarent, Inc.

About Red Herring

Red Herring is a global media company, which unites the world's best high technology innovators, venture investors and business decision makers in a variety of forums: a leading innovation magazine, an online daily technology news service, technology newsletters and major events for technology leaders around the globe. Red Herring provides an insider's access to the global innovation economy, featuring unparalleled insights on the emerging technologies driving the economy. More information about Red Herring is available online at www.redherring.com.

About Acclarent

Acclarent is a medical technology company dedicated to the development of innovative products providing new technologies to further meet the needs of ENT patients.

Acclarent's initial focus is on achieving the goals of sinus surgery with novel, endoscopic, catheter-based tools - Balloon Sinuplasty(TM) devices. Through the Balloon Sinuplasty(TM) technology and our Relieva(R) product portfolio we offer ENT patients alternatives to conventional endoscopic surgical approaches. Through our core technologies and commitment to innovation, Acclarent will continue to advance novel devices in all areas of ENT. Acclarent markets and sells its products worldwide and has been used by thousands of physicians globally. For more information about Acclarent, visit www.Acclarent.com.


'/>"/>
SOURCE Red Herring
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Acclarent, Inc. Granted Key Patent Covering Balloon Sinuplasty(TM) Technologies
2. Acclarent, Inc. Closes $26 Million Financing
3. Concurrent Technologies Corporation Awarded Contract to Support the Centers for Disease Control and Prevention with Readiness Efforts
4. Falcon Genomics Awarded Patent for Innovative Cancer Test
5. $18 million awarded to TGen and University of Pennsylvania for pancreatic cancer research
6. MHA Clinical Director Kimberly Binaso, Pharm.D. Awarded 2009 ASHP Fellow
7. University of Haifa research team awarded European Union research grant
8. $1.5 million awarded for palliative care research to improve care of seriously ill patients
9. NCQA Accreditation Status of Excellence Awarded to Blue Cross and Blue Shield of Georgia
10. MiP Consortium awarded €11 million by EDCTP
11. American Cancer Society Awarded Dual WellPoint Foundation Grants to Expand Hope Lodge Network and Patient Navigation Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... Nursing Society (ONS) wanted to create a communications platform that positions them as ... goal, Elliance and ONS reinvented their online publication as an always-on, always-fresh news, ...
(Date:3/24/2017)... ... March 24, 2017 , ... On ... Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She will present ... majority of cases litigated under ERISA involve claims for long-term disability benefits. ...
(Date:3/24/2017)... ... ... Viewers who like to educate themselves on current issues and who enjoy ... societal issues tend to appreciate and love the "Informed" series, hosted by Rob Lowe. ... for causes around the world. , Running for charity has become a ...
(Date:3/24/2017)... Southlake, Texas (PRWEB) , ... March 24, 2017 ... ... make 2017 the year of enhancements, upgrading their training and leads programs. , ... Empower University. Reserved for elite sales agents, Performance Partners is designed to teach ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding ... God #TruthwithGrace”: a devotional journal chronicling the writer’s path toward true communion with ... Walk with God #TruthwithGrace” is the creation of published author Lea Michelle Johnson, ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... KNOXVILLE, Tenn. , March 23, 2017 /PRNewswire/ ... ("Provectus" or the "Company"), a clinical-stage oncology and ... previously announced Definitive Financing Commitment Term Sheet (the ... with a group of the Company,s stockholders, who ... "PRH Group" in a Form 8-K filed with ...
(Date:3/23/2017)... March 23, 2017 The key factors ... increasing diabetic population, accelerating economic growth and increasing healthcare expenditure. ... are higher life expectancy of ESRD patients, rising demand for ... However, the expansion of the market is hindered by high ... ...
(Date:3/23/2017)... -- As a result of diagnostic technology increasing ... allergic diseases, cutting edge developments in targeted drugs ... in which pharmaceutical and biotech companies are addressing ... both a high quality meeting and a platform ... research scholars and doctors. The event will also ...
Breaking Medicine Technology: